El ticagrelor muestra beneficios en la función microvascular coronaria luego de un IAMSEST

Adherence to P2Y12 Inhibitors in Acute Coronary Syndrome: Prognosis

Non-adherence to medication in patients with acute coronary syndrome (ACS) remains to be solved; the use of polypills and a closer follow up have been tried out (follow up calls and motivation groups). Antiaggregation guidelines recommend dual antiplatelet therapy (DAPT) for at least one year after ACS.  Adherence to drug treatment is comprised of multiple<a href="https://solaci.org/en/2022/08/30/adherence-to-p2y12-inhibitors-in-acute-coronary-syndrome-prognosis/" title="Read more" >...</a>

El cierre de orejuela es seguro con los nuevos dispositivos

Left Atrial Appendage Closure Is Safe with the New Devices

Left atrial appendage closure (LAAC) in non-valvular atrial fibrillation with high risk of bleeding has shown promising results with first generation devices (with the Watchman) in the different studies. At present, we have a more modern device, the Watchman FLX, but we do not have much information about it.  To gather more data, researchers looked<a href="https://solaci.org/en/2022/08/18/left-atrial-appendage-closure-is-safe-with-the-new-devices/" title="Read more" >...</a>

The Best of the SOLACI-SOCIME 2022 Main Arena: Day 3

Lecture by Dr. Hector García García – LM-PCI: IVUS and FFR/IFR? Dr. Hector García delivered an excellent presentation on whether we should use intravascular ultrasound (IVUS) or fractional flow reserve (FFR)/instantaneous wave-free ratio (iFR) in the left main coronary artery (LMCA) to consider severe obstruction, since there is significant interobserver variability with angiography. Although the<a href="https://solaci.org/en/2022/08/11/the-best-of-the-solaci-socime-2022-main-arena-day-3/" title="Read more" >...</a>

Doble antiagregación en TAVI, simple es mejor?

High Risk of Bleeding after PCI: More Evidence for Short DAPT

Dual antiaggregation therapy (DAPT) with ASA and P2Y12 during 6 to 12 months is the indicated strategy after DES stenting to reduce ischemic events. However, in patients with elevated risk of bleeding (HBR) guideline and expert recommendations is 1-6 months, since there is plenty of evidence in favor, except for a randomized study, the MASTER<a href="https://solaci.org/en/2022/07/06/high-risk-of-bleeding-after-pci-more-evidence-for-short-dapt/" title="Read more" >...</a>

ELUVIA: DES en territorio femoropoplíteo con lesiones complejas

Two Safe Stents at Two Years in High Bleeding Risk

There is a consistent number of patients presenting high risk of bleeding. In this context, receiving dual antiplatelet therapy (DAPT) for 12 months would not be advisable. Even though the European and American guidelines recommend 1 to 6 months for chronic and acute syndromes in this group, these are often complex PCI cases, which makes<a href="https://solaci.org/en/2022/07/04/two-safe-stents-at-two-years-in-high-bleeding-risk/" title="Read more" >...</a>

¿Llegó el momento de replantear a la aspirina como la elección en prevención secundaria de MACE?

Should Aspirin Be the Standard of Secondary Prevention of MACE?

Much has been published recently on short term dual antiplatelet therapy (DAPT) both in acute (ACS) and chronic coronary syndrome (CCS) as well as safety of P2Y12 inhibitor monotherapy. When discussing secondary prevention in patients with established coronary artery disease, aspirin (ASA) has been the preferred drug for the prevention of new atherothrombotic events.  This<a href="https://solaci.org/en/2022/04/27/should-aspirin-be-the-standard-of-secondary-prevention-of-mace/" title="Read more" >...</a>

ACC 2022 | ADAPT-TAVR: Endoxaban Is Not Superior to DAPT After TAVR

DAPT-TAVR is a randomized trial that tested endoxaban in patients with no indication for anticoagulation who underwent successful transcatheter aortic valve replacement (TAVR) for symptomatic severe aortic stenosis. This study included 229 patients whose mean age was 80 years; 42% of them were male. Patients were randomized to either endoxaban 60 mg or 30 mg every 24 h or<a href="https://solaci.org/en/2022/04/13/acc-2022-adapt-tavr-endoxaban-is-not-superior-to-dapt-after-tavr/" title="Read more" >...</a>

Last Articles in TAVR in solaci.org

We share the latest works in TAVI published on our website. Last Articles in TAVR in solaci.org 01- HYDRA CE | New Models for TAVR Development The Hydra CE has shown favorable one year efficacy for the new transcatheter aortic valve model, with large effective orifice and low transvalvular gradient associated to an acceptable complications rate.  With this study,<a href="https://solaci.org/en/2022/02/14/last-articles-in-tavr-in-solaci-org/" title="Read more" >...</a>

The Most Relevant Articles of 2021 in Pharmacology

This last year, new data in pharmacology gave way to changes in practices and new hypotheses, when not simply further justified the already existing evidence. In this new editorial section, we share the most relevant of last year’s works to keep you up to speed on the main topics in the field. The Most Relevant<a href="https://solaci.org/en/2022/01/10/the-most-relevant-articles-of-2021-in-pharmacology/" title="Read more" >...</a>

The Most Relevant of 2021 In Coronary Disease

This last year, new data in coronary disease gave way to changes in practices and new hypotheses, when not simply further justified the already existing evidence.  In this new editorial section, we share the most relevant of last year’s works to keep you up to speed on the main topics in the field. The Most<a href="https://solaci.org/en/2022/01/06/the-most-relevant-of-2021-in-coronary-disease/" title="Read more" >...</a>